206 related articles for article (PubMed ID: 3119704)
1. Pseudomonas aeruginosa. II. Experimental acellular vaccine of an endotoxin and anatoxin type.
Bĕlohlávek S; Pavlík V; Rencová J; Stránský V; Nováková L; Sourek J; Výmola F
J Hyg Epidemiol Microbiol Immunol; 1987; 31(3):343-52. PubMed ID: 3119704
[TBL] [Abstract][Full Text] [Related]
2. [Pseudomonas aeruginosa preparations for active immunization].
Nazarchuk LV
Vrach Delo; 1991 Jul; (7):22-7. PubMed ID: 1771827
[No Abstract] [Full Text] [Related]
3. Active and passive mouse-protecting capacity of Pseudomonas aeruginosa protein vaccines.
Joó I; Stanislavsky ES; Zhvanetskaya MI; Mashilova GM; Gladus MA
Acta Microbiol Acad Sci Hung; 1982; 29(4):267-75. PubMed ID: 6821018
[TBL] [Abstract][Full Text] [Related]
4. Effects of somatic component of Pseudomonas aeruginosa on protective immunity in experimental mouse burn infection.
Okada K; Kawaharajo K; Kasai T; Homma JY
Jpn J Exp Med; 1980 Feb; 50(1):53-61. PubMed ID: 6770131
[TBL] [Abstract][Full Text] [Related]
5. Mouse-protection experience with monovalent Pseudomonas aeruginosa vaccine.
Sourek J; Výmola F; Zelenková L
Zentralbl Bakteriol A; 1980 Mar; 246(3):353-62. PubMed ID: 6775443
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of immunization with single and multi-component vaccines prepared from a common antigen (OEP), protease and elastase toxoids of Pseudomonas aeruginosa on protection against hemorrhagic pneumonia in mink due to P. aeruginosa.
Homma JY; Abe C; Tanamoto K; Hirao Y; Morihara K; Tsuzuki H; Yanagawa R; Honda E; Aoi Y; Fujimoto Y; Goryo M; Imazeki N; Noda H; Goda A; Takeuchi S; Ishihara T
Jpn J Exp Med; 1978 Apr; 48(2):111-33. PubMed ID: 101698
[TBL] [Abstract][Full Text] [Related]
7. An acellular vaccine from Pseudomonas aeruginosa: homologous and crossed protection between serogroups according to Habs' classification.
Berche P; Véron M; Fermanian J; Daoulas-Lebourdelles F; Guégen A
Ann Microbiol (Paris); 1979; 130(2):179-88. PubMed ID: 90473
[TBL] [Abstract][Full Text] [Related]
8. Protective characteristics of the antigen common to Pseudomonas and Vibrio and significance of bacterial endotoxins in protection against selected bacterial infections.
Sourek J
Zentralbl Bakteriol Mikrobiol Hyg A; 1985 Jul; 259(4):538-47. PubMed ID: 2413656
[TBL] [Abstract][Full Text] [Related]
9. Effects of elastase, protease and common antigen (OEP) from Pseudomonas aeruginosa on protection against burns in mice.
Kawaharajo K; Homma JY
Jpn J Exp Med; 1977 Dec; 47(6):495-500. PubMed ID: 416253
[TBL] [Abstract][Full Text] [Related]
10. [Immunogenic properties and specificity of pseudomonas aeruginosa polyvalent vaccine].
Schiller B; Lysakowska E; Owczarska K
Med Dosw Mikrobiol; 1981; 33(2):91-6. PubMed ID: 6170849
[No Abstract] [Full Text] [Related]
11. Conjugate vaccines against Pseudomonas aeruginosa and malaria.
Cryz SJ; Sadoff JC; Que JU
Contrib Microbiol Immunol; 1989; 10():166-89. PubMed ID: 2510972
[No Abstract] [Full Text] [Related]
12. Multivalent DNA vaccine protects mice against pulmonary infection caused by Pseudomonas aeruginosa.
Saha S; Takeshita F; Sasaki S; Matsuda T; Tanaka T; Tozuka M; Takase K; Matsumoto T; Okuda K; Ishii N; Yamaguchi K; Klinman DM; Xin KQ; Okuda K
Vaccine; 2006 Sep; 24(37-39):6240-9. PubMed ID: 16806598
[TBL] [Abstract][Full Text] [Related]
13. Common protective antigen (OEP) of Pseudomonas aeruginosa.
Abe C; Shionoya H; Hirao Y; Okada K; Homma JY
Jpn J Exp Med; 1975 Oct; 45(5):355-9. PubMed ID: 817054
[TBL] [Abstract][Full Text] [Related]
14. Vaccines against Pseudomonas aeruginosa results and perspectives of investigations (survey).
Joó I; Stanislavskii ES
J Hyg Epidemiol Microbiol Immunol; 1982; 26(4):417-27. PubMed ID: 6819316
[TBL] [Abstract][Full Text] [Related]
15. [Antigenic properties of Pseudomonas aeruginosa anatoxin and the protective action of antitoxic anti-Pseudomonas aeruginosa serum].
Podgornaia LG; Dziuban NF
Zh Mikrobiol Epidemiol Immunobiol; 1986 Jun; (6):67-9. PubMed ID: 3092510
[TBL] [Abstract][Full Text] [Related]
16. Application of vaccine technology to prevention of Pseudomonas aeruginosa infections.
Pier G
Expert Rev Vaccines; 2005 Oct; 4(5):645-56. PubMed ID: 16221066
[TBL] [Abstract][Full Text] [Related]
17. [Immunogenic properties of the liposomal form of Pseudomonas aeruginosa anatoxin].
Minukhin VV; Brodinova NS; Tsyganenko AIa; Ivanova NN; Vasil'chenko VN; Sennikov GA
Vestn Akad Med Nauk SSSR; 1990; (8):44-7. PubMed ID: 2125778
[TBL] [Abstract][Full Text] [Related]
18. Development of an anti-adhesive vaccine for Pseudomonas aeruginosa targeting the C-terminal region of the pilin structural protein.
Sheth HB; Glasier LM; Ellert NW; Cachia P; Kohn W; Lee KK; Paranchych W; Hodges RS; Irvin RT
Biomed Pept Proteins Nucleic Acids; 1995; 1(3):141-8. PubMed ID: 9346845
[TBL] [Abstract][Full Text] [Related]
19. [An acellular vaccine from Pseudomonas aeruginosa. II. -- Estimate of immuneserum protective effect by measure of bacterial clearance (author's transl)].
Daoulas-Le Bourdelles F; Berche P; Véron M
Ann Microbiol (Paris); 1977 Jul; 128B(1):61-71. PubMed ID: 410340
[TBL] [Abstract][Full Text] [Related]
20. Antibody titers in serum of diffuse panbronchiolitis patients administered a multicomponent Pseudomonas aeruginosa vaccine consisting of toxoids of protease, elastase and exotoxin A and a common protective antigen (OEP).
Yamamoto M; Kubota Y; Matsuura M; Homma JY
Kitasato Arch Exp Med; 1988 Sep; 61(2-3):127-35. PubMed ID: 3145352
[No Abstract] [Full Text] [Related]
[Next] [New Search]
